What happens when an intractable target becomes druggable-ish
A fish eye view of the market
In the third of our Preview series from this year’s AACR meeting, we’re taking a look at an early, if rapidly evolving competitive landscape involving several different modalities – proving there’s often more than one way to skin a cat drug a particular target!
When we last covered this topic there were barely half a dozen developments to highlight, since then this niche has rapidly exploded with a variety of molecules and different companies to add to the mix.
Some key questions facing this field include how will we move on from dose escalation studies, what combinations will make sound sense, and which modalities might offer a wider therapeutic window in order to be combinable with other approaches? People will always have favourites, so we took an unbiased look at the state of play.
It’s never as easy as it first appears…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
Do not feed the alligators is a common sign seen in the hammock areas of Florida where brackish fresh water abounds.
The romantics wearing rose tinted glasses might well think of successful cancer drug development much like the famous poem by Lord Byron;
While there has been much speculation and rah-rah over the supposed demise of oral therapies thanks to the introduction of the Inflation Reduction Act (IRA) of 2022 including the Part D Redesign, I’m increasingly finding important developments on the targeted therapies front to watch out for.
